### PATENT COOPERATION TREATY

PCT

# Y PCT

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference BCS 03-1024		FOR FURTHER ACTIO	ON	See Form PCT/IPEA/416				
International application	No.	International filing date (day)	nonth/year)	Priority date (day/month/year)				
PCT/EP2004/00937		21.08.2004		04.09.2003				
International Patent Clas	elfication (IPC) or n							
CO7D231/44 CO7D	401 <i>/</i> 04. A01N43	3/56						
0070201711, 0010	C07D231/44, C07D401/04, A01N43/56							
Applicant								
BAYER CROPSCII	ENCE S.A.							
This report is the Authority under	e international pro Article 35 and tra	eliminary examination repor ansmitted to the applicant ac	t, established by the cording to Article 3	nis International Preliminary Examining 36.				
2. This REPORT	consists of a total	of 8 sheets, including this	cover sheet.					
3. This report is a	so accompanied	by ANNEXES, comprising:						
- Cl cont to	ho annlicent and	to the International Bureau)	a total of sheets,	as follows:				
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).								
			h this Authority cor	nsiders contain an amendment that goes				
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.								
b.   (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).								
Box Re	lating to Sequenc	ce Listing (see Section 802	of the Administrativ	e instructions).				
4. This report co	ntains indications	relating to the following iter	ns:					
☑ Box No. I	Basis of the o	pinlon						
⊠ Box No. I	Priority							
	Priority		I to novelty, Inventi	ve step and Industrial applicability				
☐ Box No. II	Priority Non-establish	nment of opinion with regard						
☐ Box No. II 図 Box No. II	Priority Non-establish Lack of unity	nment of opinion with regard	with regard to nove	elty, inventive step or industrial				
☐ Box No. II ☐ Box No. II ☐ Box No. I	Priority Non-establish Lack of unity Reasoned strapplicability; Certain docu	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited	with regard to nove supporting such sta	elty, inventive step or industrial				
☐ Box No. II ☐ Box No. II ☐ Box No. II ☐ Box No. \	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defer	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited cts in the international applic	with regard to nove supporting such standard	elty, inventive step or industrial				
☐ Box No. II ☐ Box No. II ☐ Box No. II ☐ Box No. \	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defer	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited	with regard to nove supporting such standard	elty, inventive step or industrial				
☐ Box No. II ☐ Box No. II ☐ Box No. II ☐ Box No. \ ☐ Box No. \ ☐ Box No. \	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defection	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited cts in the international applic	with regard to nove supporting such standard	elty, inventive step or industrial tement				
☐ Box No. II ☐ Box No. II ☐ Box No. I ☐ Box No. \	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defection	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited cts in the international applic	with regard to nove supporting such standard cation I application	elty, inventive step or industrial tement				
☐ Box No. II ☐ Box No. II ☐ Box No. I ☐ Box No. \	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defection	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited cts in the international applic	with regard to nove supporting such standard cation I application	elty, inventive step or industrial tement				
Box No. II And Box No. II And Box No. II	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defection Certain obse	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited cts in the international appli- ervations on the Internationa	with regard to nove supporting such standard cation I application	elty, inventive step or industrial tement				
Box No. II And Box No. II Box No. II And Box No. II Box	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defect Certain obse f the demand	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited cts in the international appli- ervations on the Internationa	with regard to now supporting such states at a such state of completion of the such states at a such state of completion of the such such such such such such such such	elty, inventive step or industrial Itement				
Box No. II And Box No. II Box No. II Box No. II II Box No. II Box No. II II Box	Priority Non-establish Lack of unity Reasoned strapplicability; Certain docu Certain defect Certain obse fithe demand  ddress of the internating authority: ean Patent Office	nment of opinion with regard of invention atement under Article 35(2) citations and explanations s ments cited cts in the international appli- ervations on the Internationa	with regard to novel supporting such state of completion of the state	elty, inventive step or industrial atement  of this report				
Box No. II  Box No	Priority Non-establish Lack of unity Reasoned stapplicability; Certain docu Certain defect Certain obse f the demand	nment of opinion with regard of invention atement under Article 35(2) citations and explanations siments cited cts in the international applications on the international architectural actional	with regard to now supporting such states at a such state of completion of the such states at a such state of completion of the such such such such such such such such	elty, inventive step or industrial atement  of this report				

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/009378

	Вох	No. I	Basis of the report			
1.	With filed	h regard to the <b>language</b> , this report is based on the international application in the language in which it was d, unless otherwise indicated under this item.				
		which i	s the language of a tr rnational search (und lication of the interna	slations from the original language into the following language , anslation furnished for the purposes of: er Rules 12.3 and 23.1(b)) tional application (under Rule 12.4) examination (under Rules 55.2 and/or 55.3)		
2.	With regard to the elements* of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):					
	Des	cription	, Pages			
•	1-43	3		as originally filed		
	Clai	ms, Nu	mbers			
1-10		)		as originally filed		
		a sequ	uence listing and/or ar	ny related table(s) - see Supplemental Box Relating to Sequence Listing		
з.		The a	mendments have res	ulted in the cancellation of:		
		the the	e description, pages e claims, Nos. e drawings, sheets/figs e sequence listing <i>(sp</i> y table(s) related to s			
4.	had Su	I not be opleme  I the I the I the I the I an	een made, since they ntal Box (Rule 70.2(c) description, pages e claims, Nos. e drawings, sheets/fig e sequence listing (sp. y table(s) related to s	s necify): equence listing <i>(specify)</i> :		
	* If item 4 applies, some or all of these sheets may be marked "superseded."					

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/009378

E	3ox	No. III Non-establishment of licability	opir	nion with regard to novelty, inventive step and industrial			
_		The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- obvious), or to be industrially applicable have not been examined in respect of:					
[	_	the entire international application	entire international application,				
	×	claims Nos. 9,10					
		because:					
×		the said international application, or the said claims Nos. 9,10 relate to the following subject matter which does not require an international preliminary examination (specify):					
		see separate sheet					
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unce that no meaningful opinion could be formed (specify):						
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opir could be formed.					
		no international search report has been established for the said claims Nos.					
. 🗖		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:					
		the written form		has not been furnished			
				does not comply with the standard			
		the computer readable form		has not been furnished			
			. $\square$	does not comply with the standard			
		the tables related to the nucleon not comply with the technical r	otide equir	and/or amino acid sequence listing, if in computer readable form only, do rements provided for in Annex C- <i>bis</i> of the Administrative Instructions.			
		See separate sheet for further	deta	ils .			

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims Claims

No:

1-10

Inventive step (IS)

Yes: Claims

Claims No:

1-10

Industrial applicability (IA)

2. Citations and explanations (Rule 70.7):

Yes: Claims No: Claims 1-8

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

PCT/EP2004/009378

#### re item III:

Claims 9 and 10 have to be considered as being directed to the treatment of the human and/or animal body. Under the terms of Rule 67.1 and Art. 34 (4)a)i) PCT, the International Preliminary Examining Authority is not required to carry out an examination on such claims with respect to industrial applicability.

#### re item V:

#### 1. Prior art

The Preliminary examination procedure is based on the document cited in the International Search Report:

- D1: EP-A-0 500 209 (RHONE POULENC AGROCHIMIE) 26 August 1992 (1992-08-26)
- D2: US-A-4 971 989 (JENSEN-KORTE UTA ET AL) 20 November 1990 (1990-11-20)
- D3: US-B1-6 316 477 (AKAYAMA ATSUO ET AL) 13 November 2001 (2001-11-13)
- D4: WO 98 28279 A (RHONE POULENC AGROCHIMIE ;HAWKINS DAVID WILLIAM (GB); PILATO MICHA) 2 July 1998 (1998-07-02)
- D5: US-A-5 691 333 (PILATO MICHAEL THOMAS ET AL) 25 November 1997 (1997-11-25)

#### 2. Novelty

The present pesticidal 1-arylpyrazole derivatives differ structurally from those according to D1 to D5 by the -C(=O)-OR residue at the end of the aminoalkyl residue in position 5. Thus the claimed subject matter of claim 1 appears to fulfil the requirement of Art. 33 (2) PCT.

#### 3. Inventive step

The 1-arylpyrazole derivatives according to documents D1 to D5 are potent pesticidal compounds as compounds are the compounds of the present application. The structural difference of the present pyrazoles wherein X is C=O and Y is bond to the structural closest ones of D1 is to be seen in the -C(=O)-OR residue (see compound

1

67 in table 1 according to D1) instead of the present -O-C(C=O)R residue at the end of the aminoalkyl residue in position 5 and to those according to D2 additionally in the substituent in position 3. The pyrazoles according to D3 show the same basic structure and a very broad variety of substituents in position 5. The pyrazoles according to D4 and D5 bear a alkoxyalkylamino substituent and a alk(oxy)(thio)carbonyl substituent in position 5. Therefore the closest prior art is to be seen in document D1, since the compounds of claim 1 represent only a minimal structural change as compared to the compounds of D1.

If the problem underlying the present application were to be seen in provision of further pesticidal 1-arylpyrazole derivatives, the solution of the problem must be considered as being obvious, since the skilled man would have taken into account to replace the -O-C(C=O)R residue at the end of the aminoalkyl residue in position 5 known from D1 and D2 by the -C(=O)-OR residue for the following reasons: First of all it is known from document D3 that the residue in position 5 is not so important for the pesticidal activity, since D3 discloses that the substituent in position 5 may be varied considerably without loss of pesticidal activity. Second from D1, D3, D4 and D5 it is clearly known that it is the 1-arylpyrazole basic structure wherein the 1-arylresidue has a substitution pattern common to all those compounds as well as to the present compounds substituted by either CN, halogen, C(=NY)-X or -C=S)-NR in position 3 and a -S(O)<sub>n</sub>R group in position 4 which are of utmost importance for the biological activity. Thus, if the skilled man were to change the compounds known from D1 as little as possible from the structural point of view (in order to retain the pesticidal activity) without coming to compounds already comprised by document D1 (i.e. to create novelty against this document) and in view of the fact that similarly substituted pyrazole derivatives are already known to show pesticidal activities as well, said replacement at position 5 is an inevitable result of such considerations.

Therefore, the problem underlying the present application, is to be seen in the provision of further pesticidal 1-arylpyrazole derivatives exhibiting a surprising effect compared to the structural closest compounds of the closest prior art D1 (e.g. better or prolonged activity or a lower toxicity than the compounds of the state of the art D1). In the present case example 40 of the present application could be compared to the structural closest compounds 67 as set out in D1 (see table 1), the only structural difference being the essential feature (which renders the subject matter novel and on which an inventive step could be based), i.e. the substituent in position 5 having a -O-(C=O)-Et residue instead of a -(C=O)-O-Et residue at the end of the aminoalkyl moiety

in position 5 all other residues in positions 1, 3 and 5 and all other substituents of the phenyl residue in position 1 being identical.

An inventive step could only be acknowledged if the Applicant is able to demonstrate (preferably by means of substantial experimental data) that the problem of providing further pesticidal 1-arylpyrazole derivatives with unexpected or improved properties when compared with the structurally closest compounds of the pertinent prior art, is solved. As yet, since no such data are given in the application, the present application does not fulfil the requirement of Art. 33 (3) PCT.

#### 4. Industrial applicability

No problem arises with respect to claims 1 to 8, since the claimed compounds may be used for the preparation of industrial products.

#### re item VIII:

Present claim 1 relates to an extremely large number of possible compounds with regard of the definition of residue R<sup>12</sup> as heterocyclyl, e.g. what is comprised by such an expression without further specification. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds. The definition of residue R<sup>12</sup> as heterocyclyl thus represents clearly no reasonable generalization or obvious modification of the examples as disclosed; since this residue forms part of the 5-substituent representing the essential and no possibility has been disclosed in any of the prior art documents for this residue at the end of the substituent in position 5 being heterocyclyl without further specification (in D3 this heterocycle is specified as in corresponding claim 1), this definition should be specified according to the specification as originally filed in order comply with Art. 33 (3) and 6 PCT. In this context the Applicant is referred to the PCT Guidelines for the Preliminary Examining Authorities, Chapter 5, especially 5.43, 5.45 to 5.49 and 5.52 to 5.54: According to these Guidelines, the breadth of the claims should be such, that all the comprised compounds could be expected to solve the problem according to Art. 33 (3) PCT. Since it cannot be expected that all compounds comprised by said unspecified definition do really solve the problem underlying the present application, this expression is not admissible under Art. 33 (3) PCT should be specified according to the description as originally filed.

PCT/EP2004/009378